ATE404587T1 - Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen - Google Patents

Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen

Info

Publication number
ATE404587T1
ATE404587T1 AT99912835T AT99912835T ATE404587T1 AT E404587 T1 ATE404587 T1 AT E404587T1 AT 99912835 T AT99912835 T AT 99912835T AT 99912835 T AT99912835 T AT 99912835T AT E404587 T1 ATE404587 T1 AT E404587T1
Authority
AT
Austria
Prior art keywords
inductors
inhibitors
identifying
compositions
proteolytic antibodies
Prior art date
Application number
AT99912835T
Other languages
English (en)
Inventor
Sudhir Paul
Gennady Gololobov
Larry Smith
Original Assignee
Univ Nebraska
Larry Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska, Larry Smith filed Critical Univ Nebraska
Application granted granted Critical
Publication of ATE404587T1 publication Critical patent/ATE404587T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
AT99912835T 1998-03-23 1999-03-23 Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen ATE404587T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/046,373 US6235714B1 (en) 1998-03-23 1998-03-23 Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses

Publications (1)

Publication Number Publication Date
ATE404587T1 true ATE404587T1 (de) 2008-08-15

Family

ID=21943098

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912835T ATE404587T1 (de) 1998-03-23 1999-03-23 Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen

Country Status (16)

Country Link
US (3) US6235714B1 (de)
EP (1) EP1064308B1 (de)
JP (2) JP2002507627A (de)
KR (1) KR100748920B1 (de)
CN (1) CN100358920C (de)
AT (1) ATE404587T1 (de)
AU (1) AU760648B2 (de)
BR (1) BR9909011A (de)
CA (1) CA2324340A1 (de)
DE (1) DE69939312D1 (de)
ES (1) ES2313780T3 (de)
IL (1) IL138424A (de)
PL (1) PL343245A1 (de)
RU (1) RU2226401C2 (de)
TR (1) TR200002731T2 (de)
WO (1) WO1999048925A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855804B2 (en) 1998-03-23 2005-02-15 Board Of Regents, The University Of Texas System Covalently reactive transition state analogs and methods of use thereof
AU3511500A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
US20050043262A1 (en) * 2000-03-29 2005-02-24 Weiss Robert H. Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor
WO2002079223A2 (en) * 2001-03-31 2002-10-10 Board Of Regents, The University Of Texas System Covalently reactive transition state analogs and methods of use thereof
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
FR2825154B1 (fr) * 2001-05-22 2004-01-30 Univ Compiegne Tech Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique
WO2003035142A2 (en) 2001-10-25 2003-05-01 Emory University Catheter for modified perfusion
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
JP5253325B2 (ja) * 2002-09-04 2013-07-31 中外製薬株式会社 ＭＲＬ／ｌｐｒマウスを用いた抗体の作製
JP2006501856A (ja) * 2002-10-09 2006-01-19 インテグリジェン， インコーポレイテッド 組換え触媒ポリペプチドおよびその使用
JP4939929B2 (ja) * 2003-03-26 2012-05-30 ポール，サッドヒル タンパク質分解抗体および共有結合抗体
JP5503837B2 (ja) * 2003-03-26 2014-05-28 ポール，サッドヒル 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合
JP2007524603A (ja) * 2003-03-27 2007-08-30 ザ ユニバーシティー オブ テキサス Ｈｉｖ／エイズの受動免疫治療用ループス抗体
US20050084488A1 (en) * 2003-04-10 2005-04-21 Mulkerrin Michael G. Asparagine deaminase catalytic antibodies
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
US20090208451A1 (en) * 2003-10-17 2009-08-20 Integrigen, Inc. Halogen phosphonate monoesters
WO2005099772A2 (en) * 2004-04-13 2005-10-27 Boston Biomedical Research Institute Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death
PL1786430T3 (pl) * 2004-08-20 2013-09-30 Buck Institute For Age Res Małe cząsteczki, które zastępują lub działają agonistycznie do funkcji p53
CA2592142A1 (en) * 2004-12-22 2006-06-29 Emory University Therapeutic adjuncts to enhance the organ protective effects of postconditioning
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
WO2008133652A2 (en) * 2006-11-09 2008-11-06 Sudhir Paul Binary epitope antibodies and b cell superantigen immune stimulants
EP2452947A1 (de) 2010-11-16 2012-05-16 Münch, Jan Eine Viralinfektion steigerndes Peptid
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
EP2825553B1 (de) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispezifische antigenbindungsmoleküle und verwendungen davon
IL296285A (en) 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP3448891A1 (de) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Verfahren zur herstellung multispezifischer antigenbindender moleküle
DK3635009T3 (da) 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
KR102871690B1 (ko) 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
US20200101076A1 (en) * 2018-09-28 2020-04-02 Harrow Ip, Llc Pharmaceutical compositions for prevention or treatment of cytokine release syndrome
CN112245563A (zh) * 2020-09-29 2021-01-22 古鲟（大连）生物科技发展有限公司 可降尿酸的鲟鱼肽复合粉

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658753A (en) * 1989-04-25 1997-08-19 Paul; Sudhir Catalytic antibody components
US5194585A (en) * 1989-04-25 1993-03-16 Igen, Inc. Inhibitors of catalytic antibodies
EP0476059B1 (de) * 1989-06-08 1996-03-06 Igen, Inc. Verfahren zur erhöhung der rate der modifikation metastabiler bindungen
US5948658A (en) * 1996-06-25 1999-09-07 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody

Also Published As

Publication number Publication date
CA2324340A1 (en) 1999-09-30
CN100358920C (zh) 2008-01-02
CN1301271A (zh) 2001-06-27
BR9909011A (pt) 2000-11-28
TR200002731T2 (tr) 2001-04-20
WO1999048925A1 (en) 1999-09-30
AU3111399A (en) 1999-10-18
US6235714B1 (en) 2001-05-22
KR20010042123A (ko) 2001-05-25
DE69939312D1 (de) 2008-09-25
JP2010031016A (ja) 2010-02-12
IL138424A0 (en) 2001-10-31
RU2226401C2 (ru) 2004-04-10
US20020013274A1 (en) 2002-01-31
AU760648B2 (en) 2003-05-22
US6855528B2 (en) 2005-02-15
JP2002507627A (ja) 2002-03-12
EP1064308B1 (de) 2008-08-13
ES2313780T3 (es) 2009-03-01
US20050214295A1 (en) 2005-09-29
PL343245A1 (en) 2001-07-30
KR100748920B1 (ko) 2007-08-14
IL138424A (en) 2005-08-31
EP1064308A4 (de) 2004-08-11
EP1064308A1 (de) 2001-01-03

Similar Documents

Publication Publication Date Title
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE69732407D1 (de) Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren
DE69800716D1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
LU93274I2 (fr) Elotuzumab
ATE163195T1 (de) Lösliche liganden für cd40
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ATE403680T1 (de) Herstellung tetravalenter antikörper
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
ATE377657T1 (de) Serpin-arzneistoffe zur behandlung einer hiv- infektion und verfahren zu deren verwendung
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
BR9916209A (pt) Cadeia de receptor de citocina
DE69831007D1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
ATE557040T1 (de) Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE60239450D1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
ATE173503T1 (de) Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma
DE59611293D1 (de) Protein mit dnase-aktivität
EP1370697A4 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion und verfahren zu deren verwendung
DE60041985D1 (de) Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties